RxDoctor Payments Data

Mahesh Padmanaban

Neurology · Chicago, ILNPI 1528379674

Payments from drug & device makers

$6,640in general payments, 2019–2025

Across 26 payments — averaging $255.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • MDD US Operations, LLC$2K
  • Amneal Pharmaceuticals LLC$2K
  • Medtronic$780
  • Abbott$244
  • Teva Pharmaceuticals USA, Inc.$206
  • plus $71 from 1 others

What the payments were for

  • Consulting fees$78012%
  • Speaking & faculty fees$3,16048%
  • Travel & lodging$1,41421%
  • Food & beverage$1,08016%
  • Education$2063%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,640 in reported general payments places this provider in the 70th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$65,614
Medicare patients
252
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl15$69,570
NourianzIstradefylline23$59,291
RytaryCarbidopa/Levodopa32$57,376
Nurtec OdtRimegepant Sulfate14$24,739
Carbidopa-LevodopaCarbidopa/Levodopa367$13,214
Rasagiline Mesylate15$2,171
AmantadineAmantadine Hcl26$1,716
Carbidopa-Levodopa ErCarbidopa/Levodopa38$1,403
Primidone41$880
Selegiline Hcl12$827
Propranolol Hcl38$705
Duloxetine Hcl38$579
Gabapentin36$546
Donepezil Hcl23$488
Quetiapine Fumarate26$342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$1,760$69,57015 claims
Kyowa Kirin, Inc.Nourianz$71$59,29123 claims
Amneal Pharmaceuticals LLCRytary$1,559$57,37632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 790 neurology providers in Illinois.

Other neurology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →